VANOS

Clinical safety rating: caution

Comprehensive clinical and safety monograph for VANOS (VANOS).

How it works

VANOS (fluocinonide 0.1% cream) is a corticosteroid that binds to glucocorticoid receptors, leading to inhibition of phospholipase A2 and reduction of prostaglandin and leukotriene synthesis, resulting in anti-inflammatory, antipruritic, and vasoconstrictive effects.

What the body does with it

Metabolism	Hepatic metabolism; fluocinonide is primarily metabolized via reduction, hydrolysis, and conjugation in the liver. The exact enzymes are not fully characterized, but CYP450 enzymes may be involved.
Excretion	Primarily renal excretion (glucuronidation and sulfation); minimal biliary elimination (<5%). Approximately 60-70% of the dose is excreted in urine as metabolites, with <1% unchanged.
Half-life	The terminal elimination half-life is approximately 7.5 hours (range 5-12 hours). This supports twice-daily or once-daily dosing for sustained local effect.
Protein binding	>99% bound to plasma proteins, primarily albumin and corticosteroid-binding globulin.
Volume of Distribution	The volume of distribution (Vd) is not well-established for topical corticosteroids. For systemically absorbed fraction, Vd is estimated to be 0.1-0.5 L/kg due to high protein binding and lipophilicity.
Bioavailability	Topical: Systemic bioavailability is low (approximately 1-5%) through intact skin, but can increase to 30-50% with occlusion or compromised skin barrier (e.g., inflammation, excoriation).
Onset of Action	Topical: Clinical improvement (reduction of erythema and scaling) typically observed within 1-2 weeks of regular application.
Duration of Action	Duration of therapeutic effect after discontinuation is variable; with chronic use, effects may last several weeks to months. The duration is influenced by disease severity and skin barrier integrity.

Classification & Brands

Dosing & administration

Apply a thin layer to affected areas once or twice daily. Not for use longer than 2 weeks; maximum 15 g per day.

Dosage form	CREAM
Renal impairment	No dosage adjustment required for topical use; systemic absorption is minimal.
Liver impairment	No dosage adjustment required for topical use; systemic absorption is minimal.
Pediatric use	Not recommended for use in children under 18 years due to risk of adrenal suppression.
Geriatric use	Use with caution; apply smallest amount for shortest duration due to increased risk of skin atrophy and systemic effects.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for VANOS (VANOS).

Breastfeeding	Excretion in human milk unknown after topical application. Systemic absorption is low, so risk to nursing infant is likely minimal. Use caution; apply to smallest area for shortest duration. M/P ratio not established.
Teratogenic Risk	Pregnancy Category C. Topical corticosteroids have shown teratogenicity in animal studies; however, adequate human studies in pregnant women are lacking. Although systemic absorption is minimal, use only if potential benefit justifies risk. No specific trimester risk data; avoid prolonged use, especially in first trimester.

Warnings & precautions

■ FDA Black Box Warning

No FDA black box warning identified.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to fluocinonide or any component of the formulation","Untreated bacterial, fungal, or viral skin infections","Tuberculosis of the skin","Perioral dermatitis","Rosacea"]

Clinical Precautions

Precautions

["Hypothalamic-pituitary-adrenal (HPA) axis suppression, especially with prolonged use, large surface area, or occlusive dressings","Cushing syndrome and hyperglycemia from systemic absorption","Local adverse reactions including atrophy, striae, telangiectasias, and infection risk","Use caution in pediatric patients due to higher skin surface-to-body weight ratio","Avoid use on face, axillae, or groin unless directed by physician"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

VANOS

Clinical safety rating: caution

Comprehensive clinical and safety monograph for VANOS (VANOS).

How it works

What the body does with it

Metabolism	Hepatic metabolism; fluocinonide is primarily metabolized via reduction, hydrolysis, and conjugation in the liver. The exact enzymes are not fully characterized, but CYP450 enzymes may be involved.
Excretion	Primarily renal excretion (glucuronidation and sulfation); minimal biliary elimination (<5%). Approximately 60-70% of the dose is excreted in urine as metabolites, with <1% unchanged.
Half-life	The terminal elimination half-life is approximately 7.5 hours (range 5-12 hours). This supports twice-daily or once-daily dosing for sustained local effect.
Protein binding	>99% bound to plasma proteins, primarily albumin and corticosteroid-binding globulin.
Volume of Distribution	The volume of distribution (Vd) is not well-established for topical corticosteroids. For systemically absorbed fraction, Vd is estimated to be 0.1-0.5 L/kg due to high protein binding and lipophilicity.
Bioavailability	Topical: Systemic bioavailability is low (approximately 1-5%) through intact skin, but can increase to 30-50% with occlusion or compromised skin barrier (e.g., inflammation, excoriation).
Onset of Action	Topical: Clinical improvement (reduction of erythema and scaling) typically observed within 1-2 weeks of regular application.
Duration of Action	Duration of therapeutic effect after discontinuation is variable; with chronic use, effects may last several weeks to months. The duration is influenced by disease severity and skin barrier integrity.

Classification & Brands

Dosing & administration

Apply a thin layer to affected areas once or twice daily. Not for use longer than 2 weeks; maximum 15 g per day.

Dosage form	CREAM
Renal impairment	No dosage adjustment required for topical use; systemic absorption is minimal.
Liver impairment	No dosage adjustment required for topical use; systemic absorption is minimal.
Pediatric use	Not recommended for use in children under 18 years due to risk of adrenal suppression.
Geriatric use	Use with caution; apply smallest amount for shortest duration due to increased risk of skin atrophy and systemic effects.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for VANOS (VANOS).

Breastfeeding	Excretion in human milk unknown after topical application. Systemic absorption is low, so risk to nursing infant is likely minimal. Use caution; apply to smallest area for shortest duration. M/P ratio not established.
Teratogenic Risk	Pregnancy Category C. Topical corticosteroids have shown teratogenicity in animal studies; however, adequate human studies in pregnant women are lacking. Although systemic absorption is minimal, use only if potential benefit justifies risk. No specific trimester risk data; avoid prolonged use, especially in first trimester.

Warnings & precautions

■ FDA Black Box Warning

No FDA black box warning identified.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to fluocinonide or any component of the formulation","Untreated bacterial, fungal, or viral skin infections","Tuberculosis of the skin","Perioral dermatitis","Rosacea"]